By assessing only serious adverse events, a trend for increased risk in the rimonabant groups was observed at both dosages (5 and 20 mg), although the difference did not reach statistical significance (RR 1.16; 95%CI 0.93-1.45) (Additional file 2 ).
← all excerpts
Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.
1
—
—